SEEGNAL PRESENTS REAL-WORLD EVIDENCE ON REDUCING FALL RISK IN GERIATRIC PATIENTS AT CALTCM SUMMIT

Executive Summary

• Seegnal Inc. presented real‑world clinical results showing that AI‑enhanced prescription governance can reduce fall‑risk drivers in geriatric patients within long‑term care (LTC) settings.
• In a three‑month deployment covering 124,461 women aged 70+, 35% of prescribing alerts led to treatment modifications (~1,750 patients), indicating significant upstream risk mitigation potential.
• The findings suggest measurable cost avoidance for LTC operators and payers through reduced fall‑related hospitalizations, lower pharmacy spend, and improved quality metrics.

Key Details

• Study presented at the CALTCM Summit for Excellence (Oct 23‑25 2025).
• Population: 124,461 female patients ≥70 years old.
• Alerts analyzed: 5,088 real prescribing alerts related to alpha‑blocker use.
• Treatment modifications occurred in 35% of cases (~1,750 patients).
• High rates of temporary and repeated overrides identified, highlighting systemic risk patterns.
• Anticipated benefits for LTC operators/payers:
• Reduction in fall‑related hospitalizations.
• Lower pharmacy expenditures and medication burden.
• Improved quality metrics/star ratings.
• Enhanced value‑based contract support.
• Seegnal’s platform functions as a “Prescription Operating System,” enabling:
• Facility‑wide tracking of prescribing risk.
• Differentiation between justified exceptions and unsafe patterns.
• Policy setting, monitoring, and refinement at scale.
• Management commentary emphasizes falls as both clinical and balance‑sheet events; prescription governance is positioned as a key lever for cost control.

Notable Quotes

“In long‑term care, falls are not just clinical events – they are balance‑sheet events,” — Elad Bibi‑Aviv, CEO, Seegnal.
“Organizations don’t need more alerts. They need governance, measurement, and proof of value.” — Elad Bibi‑Aviv, CEO, Seegnal.
“Technology is essential, but the real impact on patient outcomes depends on implementation and culture.” — Dr. Shiri Guy‑Alfandary, VP Clinical & Product, Seegnal.